Seoul Veterans Hospital
Seoul, 134-060, South Korea
NCT Number: NCT01758874
PAD is caused by an increased flow resistance in atherosclerotic ischemic limbs. The investigators hypothesize that reducing blood viscosity (through controlled phlebotomy), thereby increasing the deformability of red blood cells, should reduce the flow resistance and improve tissue perfusion leading to improved clinical function and a reduction in symptoms.
Preliminary data demonstrates that phlebotomy causes a measurable change in blood viscosity as measured by the home-made rheologic method.
To evaluate the effectiveness of changes in blood viscosity, obtained through controlled phlebotomy, as a therapy to improve functional status associated with atherosclerotic ischemic limbs in pre-amputation patients.
Looking for future studies?
Notify MeMale
Interventional
Phase 2
Seoul, 134-060, South Korea
The first study is a pilot study and will act as proof of principle. This first study will include 20 patients divided into 2 groups on the basis of a randomized controlled trial: 10 patients in the control group receiving conventional treatment and 10 patients receiving therapeutic phlebotomy to lower blood viscosity. The objective is to evaluate the effect of controlled phlebotomy in patients with Grade 3, Category 5 or 6 chronic critical limb ischemia having tissue loss on Rutherford classification (Fontaine stage IV), end-stage peripheral vascular disease resistant to maximal medical therapy and where revascularization therapy (both percutaneous and surgical) has either proved insufficient or is contra-indicated or declined by the patient, usually resulting in amputation.
The primary outcome parameters will be: the salvage rate of the limb as compared with the salvage rate of the limb with conventional therapy.
Objective classification of improvement in perfusion of the distal extremities using ankle-brachial index (ABI), visual analogue pain scale, and photos.
Subjective classification of improvement in pain scale on critical limbs.
The relationship between alteration in outcome parameters (i.e., the end point is a reduced amputation rate) and blood viscosity will be evaluated as measured by the home-made rheologic methods.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
repeated phlebotomy for 4 weeks
Time frame: 5 year follow-up period
The rate of lower limb major amputation (limb salvage rate) was measured in both study arms, during 5 year follow-up period.
They would be the evidences of phlebotomy treatment directly.
Time frame: 5 year follow-up period
During 5 year follow-up period, we measured the time-to-major amputation between the two groups, phlebotomy study group and control group.
They would be the evidences of phlebotomy treatment directly.
Time frame: 5 year follow-up period
During 5 year follow-up period, we measured the mortality rate as a final result of a treatment and major amputation between the two groups, phlebotomy study group and control group.
They would be the evidences of phlebotomy treatment directly.
Time frame: Conducting study periods (4 weeks)
The relationship between alteration in outcome parameters (i.e., the end point is a reduced amputation rate) and blood viscosity will be evaluated as measured by the home-made rheologic methods.
Evaluate blood viscosity measurements with the home-made rheologic method as a monitor of and marker for the clinical effectiveness of therapeutic phlebotomy in patients with Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss.
Time frame: Conducting study periods (4 weeks)
After 4 weeks phlebotomy, we measured and confirmed the VA pain scale improvement or not in study group. They would be the evidences of phlebotomy treatment indirectly.
Time frame: Conducting study periods (4 weeks)
After 4 weeks phlebotomy, we measured and confirmed the ABI improvement or not in study group. They would be the evidences of phlebotomy treatment indirectly.
Time frame: Conducting study periods (4 weeks)
After 4 weeks phlebotomy, we measured and confirmed the complete wound healing (no more discharge from wound and complete epithelialization) between two groups. They would be the evidences of phlebotomy treatment directly.
Seoul Veterans Hospital
Other
Phase 2 Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia
Acronym: CLI-PH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05358353
Arterial Occlusive Diseases, Arteriosclerosis
Jonesboro, Arkansas, United States
View Trial DetailsNCT07383064
Arterial Occlusive Diseases, Arteriosclerosis
Aswān, Aswan Governorate, Egypt
View Trial DetailsNCT03807661
Arterial Occlusive Diseases, Arteriosclerosis
Bristol, United Kingdom
View Trial DetailsNCT03321552
Arterial Occlusive Diseases, Arteriosclerosis
Graz, Austria
View Trial Details